Announcement • Apr 02
Luvo Medical Technologies Inc. completed the acquisition of Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS). Luvo Medical Technologies Inc. signed an asset purchase agreement to acquire Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS) for CAD 0.40 million on May 22, 2025. Under the terms of the agreement, Luvo will pay Aequus a lump sum payment of CAD 0.4 million at the closing of the transaction and an ongoing royalty of 6% on gross profit attributable to the sale of Zimed PF® (less certain costs and fees) until July 29th, 2029.
The Transaction is expected to close in Q4 2025 upon the transfer of the Drug Identification Number (DIN) and is subject to certain closing conditions, including TSX Venture Exchange and shareholder approval. Aequus expects to call a special meeting of shareholders to be held in Q3 2025 for approval of the Transaction. As of October 20, 2025, The Transaction is expected to close on or before January 20, 2026. As of November 21, 2025, the transaction was approved by the Aequus shareholders at the Annual General and Special Meeting.
Blake, Cassels & Graydon LLP acted as legal advisor for Aequus Pharmaceuticals. McMillan LLP acted as legal advisor for Luvo Medical Technologies.
Luvo Medical Technologies Inc. completed the acquisition of Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS) on March 31, 2026. Announcement • Sep 23
Aequus Pharmaceuticals Inc. Appoints Giovanni Di Genova to the Board of Directors, Effective from September 12, 2025 Aequus Pharmaceuticals Inc. announced Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective September 12th, 2025. Aequus is pleased to welcome Giovanni Di Genova as a new director and are eager to work with him on the future ahead. Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Universit de Montral, respectively. He began his career in the specialty compounding pharmacy &pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals. Announcement • Sep 19
Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025 Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025. Location: british columbia, vancouver Canada 
